Pulse Biosciences Inc. (PLSE)
19.26
1.08 (5.94%)
At close: Apr 24, 2025, 3:59 PM
19.50
1.25%
After-hours: Apr 24, 2025, 07:35 PM EDT
5.94% (1D)
| Bid | 15 |
| Market Cap | 1.3B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -53.59M |
| EPS (ttm) | -0.92 |
| PE Ratio (ttm) | -20.93 |
| Forward PE | -39.02 |
| Analyst | n/a |
| Ask | 25.28 |
| Volume | 133,615 |
| Avg. Volume (20D) | 189,108 |
| Open | 18.63 |
| Previous Close | 18.18 |
| Day's Range | 18.50 - 19.28 |
| 52-Week Range | 6.59 - 25.00 |
| Beta | 1.88 |
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed i...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date May 18, 2016
Employees 75
Stock Exchange NASDAQ
Ticker Symbol PLSE
Website https://www.pulsebiosciences.com
4 weeks ago
+6%
Pulse Biosciences shares are trading higher. The c...
Unlock content with
Pro Subscription
2 months ago
+14.86%
Pulse Biosciences shares are trading higher after the company announced it appointed a new CFO.
2 months ago · businesswire.com
Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care ConferenceMIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans...
